Skip to main content

Table 3 Breast cancer subtype and selected initial treatment for patients with P-CUP with breast cancer features

From: Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site

Breast cancer subtype by using IHC

Number

Treatment given as initial therapy

ER + and or PgR +, and HER-2 -

3

TAM + LH-RH (1), arimidex (2)

ER+ and or PgR +, and HER-2 +

1

PTX + HCN (1)

ER- and PgR –, and HER-2 +

1

CBDCA+PTX + HCN (1)

ER- and PgR-, and HER-2 -

1

CBDCA+PTX

ER- and PgR-, and HER-2 unknown

1

AC (1)

  1. ER estrogen receptor, PgR progesterone receptor, HER-2 human epidermal growth factor receptor 2, TAM tamoxifen, LH-RH luteinizing hormone-releasing hormone analog, PTX paclitaxel, HCN trastuzumab, CBDCA carboplatin, AC doxorubicin and cyclophosphamide